SCHEMBL6766099

SCHEMBL6766099

COc1c(/C=C/c2ccc([N+](=O)[O-])cc2C(=O)O)cc(I)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
CTSV O60911 1/20 0.40
CTSL P07711 1/20 0.40
HTT P42858 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 4/20 0.39
TDP1 Q9NUW8 3/20 0.38
LMNA P02545 2/20 0.38
NTSR1 P30989 1/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13263699 0.84 ERN1 (0.39) ALDH1A1HTTMAPTTDP1LMNA
SCHEMBL2746025 0.82 PTGS2 (0.54) ALDH1A1MAPTTDP1CYP3A4TSHR
SCHEMBL2746028 0.82 PTGS2 (0.54) ALDH1A1MAPTTDP1CYP3A4TSHR
SCHEMBL13263483 0.78 ALDH1A1 (0.38) ALDH1A1CTSVCTSLHTTMAPT
SCHEMBL2128733 0.77 L3MBTL1 (0.45) ALDH1A1HTTTP53MAPTTDP1
SCHEMBL2128737 0.77 L3MBTL1 (0.45) ALDH1A1HTTTP53MAPTTDP1
SCHEMBL6766320 0.74 TNFRSF1A (0.38) ALDH1A1HTTMAPTKDM4EGAA
SCHEMBL2618831 0.72 ALDH1A1 (0.41) ALDH1A1HTTMAPTTDP1LMNA
SCHEMBL25413721 0.71 MAPT (0.52) ALDH1A1CTSVCTSLHTTTP53
SCHEMBL25409681 0.71 MAPT (0.52) ALDH1A1CTSVCTSLHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 ALDH1A1 938/4885CTSV 1653/4885CTSL 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.